Amundi Has $342,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

Amundi increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 224.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,614 shares of the company’s stock after buying an additional 32,241 shares during the period. Amundi’s holdings in Vir Biotechnology were worth $342,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in Vir Biotechnology by 23.9% during the third quarter. Victory Capital Management Inc. now owns 81,269 shares of the company’s stock worth $609,000 after purchasing an additional 15,696 shares during the period. Quest Partners LLC boosted its position in Vir Biotechnology by 171.4% during the third quarter. Quest Partners LLC now owns 34,455 shares of the company’s stock worth $258,000 after purchasing an additional 21,760 shares during the period. Intech Investment Management LLC bought a new position in Vir Biotechnology during the third quarter worth $191,000. Charles Schwab Investment Management Inc. boosted its position in Vir Biotechnology by 13.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after purchasing an additional 136,087 shares during the period. Finally, Valence8 US LP bought a new position in Vir Biotechnology during the third quarter worth $252,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vir Biotechnology news, EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company’s stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,859 shares of company stock valued at $326,458. 15.60% of the stock is currently owned by corporate insiders.

Vir Biotechnology Stock Up 0.9 %

VIR opened at $6.93 on Friday. Vir Biotechnology, Inc. has a twelve month low of $6.56 and a twelve month high of $14.45. The company has a 50-day simple moving average of $9.15 and a 200 day simple moving average of $8.38. The stock has a market capitalization of $950.40 million, a price-to-earnings ratio of -1.77 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 27th. Leerink Partners boosted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).